Spyre Therapeutics Stock Performance

SYRE Stock   43.21  5.40  14.28%   
On a scale of 0 to 100, Spyre Therapeutics holds a performance score of 17. The entity has a beta of 1.21, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spyre Therapeutics will likely underperform. Please check Spyre Therapeutics' expected short fall, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether Spyre Therapeutics' existing price patterns will revert.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Spyre Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Spyre Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
14.28
Five Day Return
23.39
Year To Date Return
41.3
Ten Year Return
(82.31)
All Time Return
(82.31)
Last Split Factor
1:25
Last Split Date
2023-09-08
1
Acquisition by Sloan Sheldon of 400000 shares of Spyre Therapeutics at 27.46 subject to Rule 16b-3
11/21/2025
2
Certain Series B Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
12/12/2025
3
Acquisition by King-jones Heidy of 140000 shares of Spyre Therapeutics at 30.61 subject to Rule 16b-3
01/09/2026
4
Spyre Therapeutics Valuation After New Trial Milestones And Commercial Leadership Appointment
01/13/2026
5
Acquisition by Henderson Michael Thomas of 63227 shares of Spyre Therapeutics subject to Rule 16b-3
01/21/2026
6
Disposition of 14043 shares by Turtle Cameron of Spyre Therapeutics at 32.87 subject to Rule 16b-3
02/02/2026
7
Brokerages Set Spyre Therapeutics, Inc. Target Price at 53.88
02/05/2026
8
Disposition of 957 shares by Turtle Cameron of Spyre Therapeutics at 31.82 subject to Rule 16b-3
02/11/2026
9
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superior...
02/18/2026
10
Spyre Therapeutics Receives Buy Rating from BTIG Research
02/20/2026
Begin Period Cash Flow189.2 M
Total Cashflows From Investing Activities-353.3 M

Spyre Therapeutics Relative Risk vs. Return Landscape

If you would invest  2,697  in Spyre Therapeutics on November 23, 2025 and sell it today you would earn a total of  1,624  from holding Spyre Therapeutics or generate 60.22% return on investment over 90 days. Spyre Therapeutics is currently generating 0.8601% in daily expected returns and assumes 3.8776% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Spyre, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Spyre Therapeutics is expected to generate 5.2 times more return on investment than the market. However, the company is 5.2 times more volatile than its market benchmark. It trades about 0.22 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of risk.

Spyre Therapeutics Target Price Odds to finish over Current Price

The tendency of Spyre Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 43.21 90 days 43.21 
near 1
Based on a normal probability distribution, the odds of Spyre Therapeutics to move above the current price in 90 days from now is near 1 (This Spyre Therapeutics probability density function shows the probability of Spyre Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.21 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Spyre Therapeutics will likely underperform. Additionally Spyre Therapeutics has an alpha of 0.9072, implying that it can generate a 0.91 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Spyre Therapeutics Price Density   
       Price  

Predictive Modules for Spyre Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Spyre Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
38.5042.3846.26
Details
Intrinsic
Valuation
LowRealHigh
38.9353.8857.76
Details
Naive
Forecast
LowNextHigh
38.4442.3246.20
Details
11 Analysts
Consensus
LowTargetHigh
51.6156.7162.95
Details

Spyre Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Spyre Therapeutics is not an exception. The market had few large corrections towards the Spyre Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Spyre Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Spyre Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.91
β
Beta against Dow Jones1.21
σ
Overall volatility
3.47
Ir
Information ratio 0.23

Spyre Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Spyre Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Spyre Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Spyre Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 886 K. Net Loss for the year was (208.02 M) with loss before overhead, payroll, taxes, and interest of (177.5 M).
Spyre Therapeutics generates negative cash flow from operations
Spyre Therapeutics has a frail financial position based on the latest SEC disclosures
Over 93.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Spyre Therapeutics Receives Buy Rating from BTIG Research

Spyre Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Spyre Stock often depends not only on the future outlook of the current and potential Spyre Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Spyre Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding47 M
Cash And Short Term Investments603.1 M

Spyre Therapeutics Fundamentals Growth

Spyre Stock prices reflect investors' perceptions of the future prospects and financial health of Spyre Therapeutics, and Spyre Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spyre Stock performance.

About Spyre Therapeutics Performance

By analyzing Spyre Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Spyre Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spyre Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spyre Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.20)(0.21)
Return On Capital Employed(0.29)(0.31)
Return On Assets(0.20)(0.21)
Return On Equity(0.22)(0.23)

Things to note about Spyre Therapeutics performance evaluation

Checking the ongoing alerts about Spyre Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spyre Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Spyre Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 886 K. Net Loss for the year was (208.02 M) with loss before overhead, payroll, taxes, and interest of (177.5 M).
Spyre Therapeutics generates negative cash flow from operations
Spyre Therapeutics has a frail financial position based on the latest SEC disclosures
Over 93.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Spyre Therapeutics Receives Buy Rating from BTIG Research
Evaluating Spyre Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Spyre Therapeutics' stock performance include:
  • Analyzing Spyre Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spyre Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Spyre Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Spyre Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spyre Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Spyre Therapeutics' stock. These opinions can provide insight into Spyre Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Spyre Therapeutics' stock performance is not an exact science, and many factors can impact Spyre Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Spyre Stock analysis

When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios